Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Clinical trial NCT02611778 · COMPLETED
Trial details
- NCT number
- NCT02611778
- Sponsor
- Bioeq GmbH
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-19
- Primary completion
- 2017-12-01
- Enrollment
- 712
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.